Oxeia adds Rear Admiral Don Plummer to advisory board

Oxeia Biopharmaceuticals has added former Navy SEAL Rear Admiral Don Plummer to its advisory board as the Boston biotech pushes development of OXE103 for persistent concussion symptoms. The move underscores how military brain injuries remain a major unmet medical need, with no FDA-approved drug for concussion recovery.

Why it matters: - Traumatic brain injury remains a major health challenge for U.S. service members. - Blast exposure from drones, missiles and explosive devices has affected hundreds of thousands of troops over the past two decades. - No FDA-approved drug exists to treat concussion and promote recovery. - Oxeia is positioning OXE103 as a potential treatment that could be given soon after injury to improve recovery and reduce longer-term consequences.

What happened: - Oxeia Biopharmaceuticals announced June 23, 2026, that Rear Admiral Don Plummer joined its Advisory Board. - Plummer is a former Navy SEAL with more than 30 years of service. - Oxeia is a Boston-based clinical-stage biotech company focused on persistent concussion symptoms. - Plummer said he has personally witnessed many service members suffer concussions and wants to help advance an effective treatment.

The details: - Oxeia completed a Phase 2a clinical trial at the University of Kansas Medical Center for OXE103. - The study showed an 85% responder rate for patients treated with OXE103, compared with 33% for standard care alone. - Treated patients showed lower symptom severity and better quality of life. - Oxeia said those results represent the first clinically meaningful improvement shown in persistent concussion patients. - Oxeia is raising funds for a Phase 2b trial. - The next study will enroll 160 patients at multiple sites across the U.S. later this year. - CEO Michael Wyand recruited Plummer to help build informational programs and connect Oxeia with federal agencies, including the Department of Defense and Veterans Affairs, as well as veterans seeking support and treatment options. - Wyand said Plummer’s experience across the military and biotech worlds adds needed perspective. - While serving as an admiral with the Joint Staff and Special Operations, Plummer also worked at Arcutis Biotherapeutics.

Between the lines: - Oxeia is leaning into military credibility as it tries to expand awareness of concussion treatment gaps. - The advisory board addition also signals a go-to-market strategy that includes federal agencies and the veteran community, not just clinicians and researchers. - The company is trying to turn a Phase 2a signal into a larger late-stage data package that could support broader interest in OXE103. - The Reg CF fundraising effort suggests Oxeia is using retail investor access alongside scientific and military outreach.

What's next: - Oxeia expects its Phase 2b trial to start later this year. - The company is fundraising now for that study. - Investors can buy equity through the SEC-qualified offering on StartEngine with a minimum investment of $500. - Oxeia says more information is available at the company's website and the StartEngine offering page.

The bottom line: - Oxeia is pairing a promising early clinical result with a high-profile military adviser to build momentum for a concussion drug that still needs larger trials and regulatory validation.